Six US states – New York, California, Illinois, Wisconsin, Minnesota and Washington – have joined the Federal Trade Commission's lawsuit to block Amgen's proposed nearly $28 billion acquisition of Horizon Therapeutics.
The US Federal Trade Commission’s lawsuit to potentially block the $27.8 merger of Amgen and Horizon Therapeutics is creating heightened concern in the international biopharma sector.
Calling the deal announced late last year an alarming sign for biopharma, the US Federal Trade Commission (FTC) is seeking to block the closing of Amgen’s proposed $28 billion acquisition of Horizon Therapeutics with a temporary restraining order and preliminary injunction.
